Search PubMed⌕ Search

Biomedical subjects

C R Clarke

Publications and source records attributed to C R Clarke.

65 records · Page 4Linked to original sources
PubMed1978

Neurological manifestations of Paget's disease.

The neurological features of 96 patients whose skull and spinal X-rays showed the features of Paget's disease of bone were reviewed. The clinical phenomena were compared with those in another group of patients, identified by having a normal skull X-ray. Cranial nerve lesions and spinal syndromes could be attributed to the Paget's disease in many cases but the evidence did not suggest that other clinical phenomena such as dementia and epilepsy were related to the bony changes. Amongst cranial nerve lesions deafness is certainly attributable to Paget's disease, hemifacial spasm when combined with other signs is probably related, and possibly also trigeminal neuralgia. Basilar invagination can be asymptomatic, but deafness, hemifacial spasm and pyramidal signs were more prevalent in its presence. The importance of reviewing the cause and effect relationship between Paget's disease and neurological problems is discussed in the context of the therapeutic use of calcitonin.

Aged↗
PubMedDate not supplied

Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent.

The metabolism of BRB-I-28 (7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane), a novel class Ib antiarrhythmic agent, was characterized in vivo in dogs and rats and in vitro with rat liver microsomal preparations containing a NADPH-generating system. In dogs, rats and the in vitro hepatic microsomal oxidation system, BRB-I-28 was extensively metabolized to form 7-benzyl-3-thia-7-azabicyclo [3.3.1]nonane-3-oxide (I), a major metabolite. The metabolite I was produced via S-oxidation, presumably by the hepatic P-450 system. Formation of minor metabolite, 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane (II) via the oxidation of the benzylic site was also identified in rats. Following intravenous and oral administration of BRB-I-28 to dogs, the plasma concentration of major metabolite I could be test described by a 1-compartmental model. The plasma AUC of metabolite I was 20% (i.v.) and 179.4% (oral) of that of the parent BRB-I-28, respectively, suggesting that BRB-I-28 was metabolized significantly by the first pass effect following oral administration. Extensive metabolism of BRB-I-28 to form metabolites I and II, which have demonstrated much lower antiarrhythmic activities, further supports previously observed pharmacodynamic and pharmacokinetic findings.

Animals↗
PubMedDate not supplied

Use of 99mTc-mercaptoacetyltriglycine to evaluate renal function in horses.

Ten healthy horses were injected intravenously with 99mTc-MAG3 and the disappearance of radioactivity from the blood was measured. The total body clearance (Cl(B)) and elimination half-life (t1/2(beta)) were 7.9 +/- 1.5 ml/kg/minute and 32.8 +/- 4.1 minutes, respectively. The disappearance of 99mTc-MAG3 from the blood of 2 horses with compromised renal function was also measured. The data suggest that 99mTc-MAG3 is a useful and clinically applicable radiopharmaceutical for measurement of effective renal blood flow in the horse.

Animals↗
PubMedDate not supplied

Three journeys to high altitude: medicine, Tibetan thangkas, and Sepu Kangri.

This article begins by highlighting the work of several pioneers of altitude medicine, and their achievements in physiology and clinical observation. Tibetan medicine of the 17th century is then introduced, particularly the medical paintings (thangkas) and the conduct of traditional physicians. Finally, I mention recent British mountain exploration in central Tibet during 1996, 1997 and 1998 and the challenge of Sepu Kangri which, at 6,995m, is the highest peak of the eastern Nyangla Qen Tangla Shan.

Altitude Sickness↗
PubMedDate not supplied

Cerebral siderosis: a complication of anticoagulant therapy?

The authors report a case of cerebral siderosis, a rare disease that generally follows multiple small episodes of subarachnoid hemorrhage from any source, following long-term anticoagulation and minor head injury, and document the features on MR, which demonstrates characteristic hypointensity in the meninges on T2-weighted scans.

Anticoagulants↗
PubMedDate not supplied

Do research interviews cause distress or interfere in management? Experience from a study of cancer patients.

Research interviews with seriously ill patients are now often undertaken in quality of life research. Clinicians may be approached by researchers wishing to study their patients, and may be worried at some ethical aspects of interviewing. Concerns may include potential distress which interviews may cause, that they may interfere with the doctor-patient relationship, and perhaps, a scepticism that techniques addressing psychosocial concerns produce only 'soft' data. However, interview methods are a valuable tool for medical sociologists, nurse researchers and others. We discuss here some reflections following a study that involved interviewing severely ill patients with incurable malignant cerebral glioma. We use our observations to answer concerns and to discuss problems that arose. We suggest areas researchers and clinicians might consider before embarking on such collaboration.

Adult↗